Does SummaCare Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines that drive type 2 inflammatory disease. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults, and the label has since expanded to cover multiple conditions [1]. Because the drug costs roughly $37,000 to $46,000 per year at list price, insurance authorization is not optional for most patients, it is the only realistic path to access [2].

SummaCare is a northeast Ohio-based health plan affiliated with Summa Health System. Its formulary and prior authorization policies follow standard commercial managed-care practices, but the specific clinical criteria, step-therapy requirements, and appeal timelines differ from national carriers. Understanding SummaCare's process specifically can save patients weeks of delay.

FDA-Approved Indications for Dupixent

The FDA has approved dupilumab for six distinct indications as of 2024 [1]:

• Moderate-to-severe atopic dermatitis in patients age 6 months and older
• Add-on maintenance treatment of moderate-to-severe asthma (age 12+) with an eosinophilic phenotype or oral corticosteroid-dependent asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults
• Eosinophilic esophagitis (EoE) in patients age 12+ weighing at least 40 kg
• Prurigo nodularis in adults
• Chronic obstructive pulmonary disease (COPD) with type 2 inflammation (approved June 2024) [3]

SummaCare's medical and pharmacy policies track FDA-approved indications, so a documented diagnosis and meeting clinical criteria for any one of these conditions forms the foundation of an approvable prior authorization request.

The Clinical Evidence Base SummaCare Reviewers Reference

Insurers rely on published trial data when writing clinical criteria. For atopic dermatitis, the key SOLO-1 and SOLO-2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA 0/1 response (clear or almost clear skin) in 38% of patients versus 10% on placebo at week 16, with P<0.001 [4]. The LIBERTY AD CHRONOS trial (N=740, 52 weeks) confirmed durable benefit with a 36% IGA 0/1 rate on dupilumab plus topical corticosteroids versus 12% on placebo plus topical corticosteroids [5].

For asthma, the QUEST trial (N=1,902) showed dupilumab reduced annualized severe exacerbation rates by 47.7% in patients with baseline blood eosinophils at or above 300 cells/microliter [6]. These effect sizes are what payers use to justify coverage and to set eosinophil thresholds in their criteria.

SummaCare's Prior Authorization Requirements for Dupixent

Prior authorization (PA) is mandatory for Dupixent across all SummaCare commercial, Medicare Advantage, and Medicaid managed-care products. The PA process begins with your prescribing physician submitting a request through SummaCare's specialty pharmacy or utilization management portal.

Typical Clinical Criteria SummaCare Applies

While SummaCare's exact published criteria may update annually, commercially available health plan policy templates and Ohio Medicaid managed care standards give a reliable picture of what is required [7]:

For atopic dermatitis:

• Confirmed diagnosis of moderate-to-severe atopic dermatitis by a board-certified dermatologist or allergist
• EASI score of 16 or greater, or IGA score of 3 or greater, documented in the medical record
• Trial and inadequate response to at least one medium-to-high potency topical corticosteroid for a minimum of 4 weeks
• Trial and inadequate response or documented contraindication to at least one topical calcineurin inhibitor (e.g., tacrolimus 0.1%)
• Age at or above the FDA-approved threshold for the requested formulation

For asthma:

• Severe asthma confirmed by spirometry (FEV1/FVC <0.7 post-bronchodilator on at least one test)
• Blood eosinophil count of 150 cells/microliter or greater at baseline (some plans require 300 cells/microliter)
• Current use of medium-to-high dose inhaled corticosteroid plus a second controller medication
• At least two severe exacerbations requiring systemic corticosteroids in the prior 12 months, or ongoing oral corticosteroid dependence [8]

For CRSwNP:

• CT-documented bilateral nasal polyps
• Prior functional endoscopic sinus surgery (FESS) or documented medical contraindication to surgery
• Ongoing symptoms despite intranasal corticosteroid spray for at least 12 weeks [9]

Documentation Your Prescriber Must Submit

A complete PA packet typically includes:

• Office notes documenting disease severity scores
• Lab results (eosinophil counts for asthma/EoE indications)
• Pharmacy records or prescriber attestation proving prior therapy failure
• Current medication list
• Diagnosis codes (ICD-10-CM L20.89 for atopic dermatitis, J45.51 for severe persistent asthma, J33.0 for nasal polyp, etc.)

Incomplete submissions are the single most common reason for initial denials that have nothing to do with medical necessity. Dermatology and allergy practices familiar with biologic PA often have a dedicated coordinator who manages this documentation.

What Happens After SummaCare Receives the PA Request?

SummaCare, like all Ohio-regulated insurers, must process standard PA requests within 15 calendar days and urgent requests within 72 hours under Ohio Revised Code 3922.12. Missing that window entitles the member to a deemed approval in some circumstances [10].

If the PA Is Approved

Dupixent is dispensed through a specialty pharmacy, not a retail chain. SummaCare typically contracts with Accredo, CVS Specialty, or a similar specialty pharmacy. The drug ships refrigerated directly to the patient's home or physician's office. Your specialty-tier cost share applies, which on most SummaCare commercial plans runs between $150 and $500 per fill before any manufacturer assistance.

If the PA Is Denied

A denial notice must state the specific clinical reason and cite the relevant coverage policy. Common denial reasons include:

• Inadequate documentation of prior therapy failure
• Disease severity scores not meeting threshold
• Requested indication not yet FDA-approved at time of submission
• Age below the FDA-approved threshold for the requested formulation

Upon denial, SummaCare must offer an internal appeal. Ohio law gives members at least 60 days to file that appeal [11]. If the internal appeal also fails, members have the right to an independent external review through the Ohio Department of Insurance under Ohio Revised Code 3922.16 [10].

The External Review Option

External review is underused. A study published in JAMA Internal Medicine found that enrollees win external reviews of biologic drug denials at rates between 39% and 59% depending on the condition, meaning nearly half of all appealed denials are overturned [12]. Filing the external review request costs nothing and does not require an attorney.

Step Therapy: What You Must Try Before Dupixent

Step therapy, sometimes called "fail first," requires patients to try and fail less expensive treatments before a payer will authorize a biologic. Ohio passed step therapy reform legislation (Ohio Revised Code 3902.11) that limits step therapy to clinically appropriate alternatives and requires override pathways when step therapy would cause harm [13].

Atopic Dermatitis Step Therapy

SummaCare's step protocol for atopic dermatitis typically requires documented trials of:

1. Topical corticosteroids (medium-to-high potency, minimum 4 weeks)
2. Topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%)
3. Phototherapy (narrowband UVB), unless contraindicated or impractical

A 2023 systematic review in the Journal of the American Academy of Dermatology confirmed that dupilumab produces superior outcomes compared with cyclosporine and methotrexate in head-to-head real-world data, supporting the clinical rationale for its use after conventional failure [14].

Asthma Step Therapy

For severe asthma, step therapy requires documentation that the patient is already on Step 4 or Step 5 therapy per GINA 2023 guidelines, meaning at minimum a medium-to-high dose ICS combined with a long-acting beta-agonist, with persistent symptoms or frequent exacerbations [8].

Override Criteria

Ohio law requires SummaCare to grant a step therapy override when the required prior drug is contraindicated, caused an adverse reaction, or is clinically equivalent to a prior failed therapy. Your prescriber should explicitly request the override and document the reason in the PA letter if any of these conditions apply.

How Much Will Dupixent Cost Through SummaCare?

Even with coverage, specialty-tier cost sharing can make Dupixent unaffordable. Three programs reduce or eliminate that cost share.

Sanofi/Regeneron MyWay Co-Pay Program

Commercially insured patients (not Medicare or Medicaid) may enroll in the Dupixent MyWay program directly at dupixent.com. Eligible patients may pay as little as $0 per month, with a maximum benefit of $13,000 per calendar year [15]. Enrollment takes roughly 10 minutes online or by phone at 1-844-387-4936.

Patient Assistance Program (PAP)

Patients without insurance or whose income falls at or below 600% of the federal poverty level may qualify for free drug through Sanofi's Patient Assistance Program. Applications are submitted through NeedyMeds or directly through the manufacturer [16].

State Pharmaceutical Assistance Programs

Ohio does not operate a general pharmaceutical assistance program for working-age adults, but the Ohio Benefits Medicaid program covers dupilumab for eligible low-income patients meeting clinical criteria [7].

The table below outlines the cost pathway depending on insurance status:

| Scenario | Estimated Monthly Out-of-Pocket | |---|---| | SummaCare commercial + MyWay co-pay card | $0 to $35 | | SummaCare commercial, no co-pay card | $150 to $500 | | SummaCare Medicare Advantage | $200 to $800 (Part D gap rules apply) | | No insurance, PAP-eligible | $0 | | No insurance, PAP-ineligible | $3,600 to $3,900 (list price) |

Dupixent for Specific Conditions: Coverage Nuances

Atopic Dermatitis in Children

The FDA approved dupilumab for atopic dermatitis down to age 6 months in 2022 following the LIBERTY AD PRESCHOOL trial (N=162), which showed 28.4% of treated children aged 6 months to 5 years achieved IGA 0/1 at week 16 versus 4.3% on placebo (P<0.001) [17]. SummaCare's PA criteria for pediatric patients typically require the same severity thresholds and prior therapy failure, with doses weight-adjusted per FDA labeling.

Prescribers submitting pediatric PAs should explicitly cite the FDA-approved pediatric labeling and include the child's weight in kilograms, as the 200 mg/2 mL formulation (used for patients 15 to 29 kg) differs from the 300 mg adult syringe.

Eosinophilic Esophagitis

The LIBERTY EoE TREET trial (N=239) demonstrated that dupilumab 300 mg weekly for 24 weeks achieved histologic remission (peak esophageal eosinophil count <6 per high-power field) in 59.5% of patients versus 5.6% on placebo [18]. SummaCare PA criteria for EoE generally require:

• Confirmed EoE diagnosis by esophageal biopsy showing at least 15 eosinophils per high-power field
• Documented failure of proton pump inhibitor therapy for at least 8 weeks
• Gastroenterology or allergy specialist prescribing the drug

Prurigo Nodularis

The PRIME and PRIME2 trials (combined N=406) showed dupilumab reduced the Investigator Global Assessment-Prurigo Nodularis score by at least 4 points in 58% of patients at week 24 versus 21% on placebo [19]. Prurigo nodularis is an underserved condition with few alternatives, and SummaCare's step therapy requirements here are typically less extensive than for atopic dermatitis, given the limited evidence base for conventional systemic treatments.

COPD with Type 2 Inflammation

The BOREAS trial (N=939) showed dupilumab 300 mg every two weeks reduced moderate-to-severe COPD exacerbation rates by 34% versus placebo over 52 weeks in patients with blood eosinophils of 300 cells/microliter or greater (P<0.001) [3]. Because FDA approval for COPD came in June 2024, SummaCare's clinical criteria for this indication may still be in draft form. Prescribers should contact SummaCare's medical director's office directly to confirm current criteria before submitting.

How to Submit a Dupixent PA to SummaCare: A Step-by-Step Process

Getting a PA approved on the first submission saves weeks of back-and-forth. The steps below reflect standard SummaCare commercial plan procedures:

Step 1: Confirm Formulary Placement

Log into the SummaCare member portal or call the number on the back of your insurance card to confirm the current formulary tier and any quantity limits for your specific plan year. Formulary changes on January 1 each year.

Step 2: Obtain the PA Request Form

SummaCare's utilization management forms are available through the provider portal. Many specialty pharmacies, including Accredo and CVS Specialty, will initiate the PA on the prescriber's behalf once they receive a valid prescription.

Step 3: Assemble the Clinical Package

Your prescriber's office should compile:

• Two most recent office notes with documented severity scores
• Lab results (eosinophils, IgE if relevant)
• Written attestation of prior therapy failure with dates and doses
• A brief cover letter citing the FDA-approved indication and relevant trial data

Citing the SOLO-1/SOLO-2 results [4] and the CHRONOS 52-week durability data [5] directly in the cover letter signals to the SummaCare reviewer that the prescriber understands the clinical basis for the request.

Step 4: Track the Decision Deadline

Note the submission date. Standard decisions are due within 15 calendar days. If you have not received a decision by day 12, call SummaCare's utilization management line to confirm receipt and ask for an estimated decision date.

Step 5: Act Within 24 Hours of a Denial

Read the denial letter carefully. If the reason is a missing document, supplement the record and request reconsideration the same day. If the reason is a clinical disagreement, escalate immediately to a peer-to-peer review, a 15-minute call between your prescriber and SummaCare's reviewing physician that overturns denials in a significant proportion of cases [20].

Appeals and External Review: Your Legal Rights

Ohio law gives SummaCare members two layers of appeal protection.

Internal Appeal

File within 60 days of denial. Include a written statement from your prescriber explaining why step therapy alternatives are inappropriate or have already failed. Request a peer-to-peer review simultaneously. SummaCare must render a decision within 15 days for standard appeals and 72 hours for expedited appeals involving urgent medical need [10].

External Review

If the internal appeal fails, request external review through the Ohio Department of Insurance at insurance.ohio.gov. An independent review organization (IRO) staffed by board-certified physicians in the relevant specialty reviews the case without any financial relationship with SummaCare. As noted above, external reviews of biologic drug denials are overturned in favor of the patient in nearly half of all cases [12]. File the external review request within 45 days of the internal appeal denial.

Legal Assistance

Ohio Legal Help (ohiolegalhelp.org) and the Patient Advocate Foundation (patientadvocate.org) offer free case management for insurance disputes. The Patient Advocate Foundation resolved over 85,000 insurance access cases in 2023 and assigns a dedicated case manager to eligible patients within 3 business days [21].

Monitoring and Renewal PAs

Dupixent PA approvals are typically granted for 12 months and require renewal. At renewal, SummaCare reviewers generally want to see:

• Documented clinical response (reduction in EASI, IGA, or exacerbation rate)
• Ongoing diagnosis and current medication list
• No safety signals (conjunctivitis, injection site reactions, eosinophilia requiring dose change)

A 2022 analysis in Dermatology and Therapy (N=4,025 real-world patients) found that 83% of dupilumab-treated atopic dermatitis patients maintained EASI-50 response at 52 weeks, providing the kind of outcome documentation that supports renewal approvals [22]. Your prescriber should routinely document objective response measures at each visit, not just subjective improvement, because renewal denials are most commonly triggered by the absence of documented severity scores rather than actual lack of response.